Nanette Ryan
Biographic Data
| ID | 3582035 |
|---|---|
| NAME | Nanette Ryan |
| GIVEN NAMES | Nanette |
| FAMILY NAME | Ryan |
| SIGNATURE | RYAN N |
| AFFILIATIONS | National University of Singapore |
| ORCID | 0009-0007-7540-149X |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 6 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
The ethics of wegovy for children
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) marketed as Wegovy, has gained international attention for its appetite-suppressing and weight-loss effects. Approved by the U.S. FDA in 2022 for paediatric use in children aged 12 and older, Wegovy has since received similar approvals in several countries. Despite this, uptake among youth has been limited. While some clinicians advocate for broader paediatric use of Wegovy as an …
The ethics of Wegovy
Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has attracted significant global attention for its appetite-suppressing and weight-loss effects. Approved for pediatric use in children aged 12 and older, Wegovy has been described as a “miracle drug” and hailed as a potential solution to the so-called “obesity epidemic.” However, prescribing medication to children raises complex …
The Ethics of Ozempic and Wegovy
Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market. Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most commonly to treat type II diabetes. To date, the results of semaglutide for the treatment of type II diabetes have been overwhelmingly positive. It is for the drug’s effects on appetite suppression and weig…
The Ethics of Wegovy in Pediatric Mental Health
Semaglutide (Wegovy), a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA), has attracted global attention for its appetite‐suppressing and weight‐loss effects. Approved by the U.S. FDA in 2022 for adolescents aged 12 and older, it has since been authorized in several other countries. Despite this, its use among youth remains limited, with ongoing concerns about its long‐term safety, efficacy, and suitability during periods of growth and develop…
Even with diet and exercise, Ozempic use reduces perceived effort and praiseworthiness of resulting weight loss
The injectable medication Ozempic (semaglutide) has demonstrated unprecedented effectiveness in promoting significant weight loss. However, its use has sparked moral debates, with critics dismissing it as a mere "shortcut" compared to traditional methods like diet and exercise. This study investigates how weight loss method-Ozempic, diet/exercise, or a combination of both-impacts perceptions of effort, praiseworthiness, and identity/value change.…
Self-respect & Childhood
No prominent works on this page.
Self-respect & Childhood
Even with diet and exercise, Ozempic use reduces perceived effort and praiseworthiness of resulting weight loss
The injectable medication Ozempic (semaglutide) has demonstrated unprecedented effectiveness in promoting significant weight loss. However, its use has sparked moral debates, with critics dismissing it as a mere "shortcut" compared to traditional methods like diet and exercise. This study investigates how weight loss method-Ozempic, diet/exercise, or a combination of both-impacts perceptions of effort, praiseworthiness, and identity/value change.…
The ethics of wegovy for children
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) marketed as Wegovy, has gained international attention for its appetite-suppressing and weight-loss effects. Approved by the U.S. FDA in 2022 for paediatric use in children aged 12 and older, Wegovy has since received similar approvals in several countries. Despite this, uptake among youth has been limited. While some clinicians advocate for broader paediatric use of Wegovy as an …
The ethics of Wegovy
Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has attracted significant global attention for its appetite-suppressing and weight-loss effects. Approved for pediatric use in children aged 12 and older, Wegovy has been described as a “miracle drug” and hailed as a potential solution to the so-called “obesity epidemic.” However, prescribing medication to children raises complex …
The Ethics of Ozempic and Wegovy
Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market. Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most commonly to treat type II diabetes. To date, the results of semaglutide for the treatment of type II diabetes have been overwhelmingly positive. It is for the drug’s effects on appetite suppression and weig…
The Ethics of Wegovy in Pediatric Mental Health
Semaglutide (Wegovy), a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA), has attracted global attention for its appetite‐suppressing and weight‐loss effects. Approved by the U.S. FDA in 2022 for adolescents aged 12 and older, it has since been authorized in several other countries. Despite this, its use among youth remains limited, with ongoing concerns about its long‐term safety, efficacy, and suitability during periods of growth and develop…
Diabetes Treatment and Management (3 works) · Best interests (2 works) · Clinical Ethics (2 works) · Law (2 works) · MEDLINE (2 works) · Pharmaceutical studies and practices (2 works) · Pharmacology and Obesity Treatment (2 works) · Political science (2 works) · Attachment and Relationship Dynamics (1 works) · Autonomy (1 works)